During the last decade, our group has explored new therapeutic strategies for CPT2 and VLCAD deficiencies, based on the use of drugs or natural compounds that might pharmacologically stimulate residual enzyme activities and β-oxidation capacities. Here, CPT2 is linked to very long chain acyl-CoA dehydrogenase deficiency.